CERO Therapeutics closes additional $397,600 private placement of Series D Preferred Stock

CERO THERAPEUTICS HOLDINGS, INC.

Issued 497 shares of Series D convertible preferred stock for gross proceeds of approximately $397,600.
Sale conducted as an Additional Closing under previously announced Securities Purchase Agreement dated April 21, 2025.
Exempt from registration under Section 4(a)(2) and Rule 506 of the Securities Act.
Shares are convertible into common stock; terms set forth in Certificate of Designations filed April 22, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.